In general, a biomarker refers to a certain characteristic biochemical index in an ordinary physiological, pathological, or therapeutic process that can be objectively measured and evaluated. By measuring the biomarker, we can learn and the current biological process of the body.

Checking a disease-specific biomarker may be helpful for disease identification, early diagnosis, prevention, and monitoring during treatment. Many traditional pharmaceutical companies and emerging biotechnology companies often use biomarkers in the drug development process to accelerate the drug development process and ensure product safety. When designing an assay kit, the first thing that needs to be clarified is the purpose of the biomarker data. For non-critical biomarkers, such as internal analysis, biomarker screening, etc., it can be designed according to actual needs. For key biomarkers, it is necessary to perform standard curve and sample concentration tests, parallelism, and selectivity test, QC, etc.

Project Experience

  • Ipilimumab (CTLA-4), Conbercept, ranibizumab, ramucirumab, Atezolimab (PD-L1), Pertuzumab, Cetuximab Erbitux (Cetuximab), CD40 antibody, SOST antibody, IgE antibody, MCF antibody, PCSK9 antibody, IL-6 antibody, IL-17A antibody, IL-23 antibody, etc.

Bispecific/Trispecific Antibodies:

  • EqCAM/CD3, CD3/Her2, PDL1/TGF-β, PDL1/VEGF, (nanobody 1), EGFR/IL-10,CTLA-4/PD1, Her2/Her2